Prognostic implications of low transferrin saturation in patients with primary myelofibrosis by Lucijanić, Marko et al.
     
 
Središnja medicinska knjižnica 
 
 
 
 
Lucijanić M., Prka Ž., Pejša V., Štoos-Veić T., Lucijanić J., Kušec R. 
(2018) Prognostic implications of low transferrin saturation in patients 
with primary myelofibrosis. Leukemia Research, 66. pp. 89-95. ISSN 
0145-2126 
 
 
http://www.elsevier.com/locate/issn/01452126 
 
http://www.sciencedirect.com/science/journal/01452126 
 
http://dx.doi.org/10.1016/j.leukres.2018.01.017 
 
 
 
 
http://medlib.mef.hr/2899 
 
 
 
University of Zagreb Medical School Repository 
http://medlib.mef.hr/ 
 
Title: Prognostic implications of low transferrin saturation in patients with primary 
myelofibrosis 
 
Authors:  
Marko Lucijanic 
a
, Zeljko Prka 
b
, Vlatko Pejsa 
a, b
, Tajana Stoos-Veic 
c, d
, Jelena Lucijanic 
e
, 
Rajko Kusec 
a, b, f
 
 
Affiliations: 
a
 Hematology Department, University Hospital Dubrava, Av. Gojka Suska 6, 10000 Zagreb, 
Croatia 
b
 School of Medicine, University of Zagreb, Salata 3, 10000 Zagreb, Croatia 
c
 Department of Clinical Cytology and Cytometry, University Hospital Dubrava, Av. Gojka 
Suska 6, 10000 Zagreb, Croatia 
d
 Faculty of Medicine, University of Osijek, Ul. Josipa Huttlera 4, 31000 Osijek, Croatia 
e
 Health Care Center Zagreb-West, Prilaz baruna Filipovica 11, 10000 Zagreb, Croatia 
f
 Divison of Molecular Diagnosis and Genetics, Clinical Department of Laboratory 
Diagnostics, University Hospital Dubrava, Av. Gojka Suska 6, 10000 Zagreb, Croatia 
 
Corresponding author: Marko Lucijanic, MD PhD, Hematology Department, University 
hospital Dubrava, Av. Gojka Suska 6, 10000 Zagreb. Tel: +38512902444 
Email: markolucijanic@yahoo.com 
2 
 
Abstract: Objectives: Transferrin saturation (TSAT) 20% or less is considered to represent 
functional iron deficiency in the context of malignant disease, phenomenon mediated through 
inflammatory changes of iron homeostasis. We aimed to investigate clinical and prognostic 
significance of low TSAT in patients with primary (PMF) and secondary myelofibrosis 
(SMF), malignant diseases characterized by strong inflammatory milieu.  
Methods: We retrospectively analyzed 87 patients with myelofibrosis and compared TSAT 
with disease specific parameters. 
Results: One-third of patients had TSAT ≤20%. Lower TSAT was significantly associated 
with Janus-kinase-2 (JAK2) mutation (P=0.007), transfusion independency (P=0.003), higher 
platelets (P=0.004), lower mean-corpuscular-volume (P<0.001), lower ferritin (P<0.001), 
higher absolute-neutrophil-count (P=0.027), lower absolute-lymphocyte-count (P=0.041) and 
lower albumin (P=0.018). PMF patients presenting with low TSAT (≤20%) experienced 
significantly shorter overall-survival (OS) (HR=2.43; P=0.017), whereas TSAT did not affect 
OS of SMF patients (HR=1.48; P=0.623). Low TSAT remained significantly associated with 
inferior OS in PMF in a series of multivariate Cox regression models comparing its properties 
to anemia, transfusion dependency, ferritin and Dynamic-International-Prognostic-System 
(DIPSS).  
Conclusions: Low TSAT has detrimental effect on survival of PMF patients. This effect is 
independent of anemia and of ferritin levels that seem to be better at representing iron 
overload in PMF patients. 
Keywords: Philadelphia chromosome negative myeloproliferative neoplasm; Primary 
myelofibrosis; Survival; Iron metabolism, Transferrin saturation; Functional iron deficiency  
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1. Introduction: 
Philadelphia chromosome negative myeloproliferative neoplasms (Ph- MPNs) [1] are 
malignant diseases developing from clonally transformed hematopoietic stem cell [2]. They 
have classically been divided into primary myelofibrosis (PMF), polycythemia vera (PV) and 
essential thrombocytosis (ET). A majority of Ph- MPN patients bear a mutation in either of 
Janus-kinase-2 (JAK2), Calreticulin (CALR) or Myeloproliferative-leukemia-virus-oncogene 
(MPL) genes [3] resulting in constitutive activation of JAK/signal-transducer-and-activator-
of-transcription (STAT) signaling pathway, strong myeloproliferation and high inflammatory 
atmosphere characteristic for these diseases [4]. PMF is the most aggressive among Ph- 
MPNs and bears the highest risk of transformation to acute leukemia [5] and death [6]. It is 
characterized by development of bone marrow fibrosis, varying number and degree of 
myeloid lineage cytopenias, prominent constitutional symptoms, and progressive 
hepatosplenomegaly due to activation of extramedullary hematopoiesis. PV and ET can 
develop substantial degree of bone marrow fibrosis and PMF-related features during disease 
course when these conditions are termed secondary myelofibrosis (SMF) [7]. Although 
similar in clinical presentation and prognosis, PMF and post-PV/post-ET SMF still harbor 
different molecular backgrounds that resemble diseases of origin [8]. The risk of death in 
myelofibrosis patients can be assessed using the International Prognostic Scoring System 
(IPSS) at the time of diagnosis [9], or the Dynamic International Prognostic Scoring System 
(DIPSS) during course of the disease [10]. Both prognostic systems assign points for older 
age, higher white blood cell (WBC) count, lower hemoglobin level, presence of circulatory 
blasts and presence of constitutional symptoms; higher score indicates worse prognosis. 
Transfusion dependency, thrombocytopenia and unfavorable karyotype are additionally 
included as negative prognostic factors into DIPSS-plus prognostic model [11].  
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Regulation of iron metabolism is disturbed in Ph- MPN patients, due to dysregulated 
inflammatory cytokine expression, iron overload introduced through red blood cell (RBC) 
transfusions (in myelofibrosis) and iron depletion due to phlebotomies (in PV). Hepcidin, a 
central regulator of iron metabolism, is overproduced in PMF patients and both high ferritin 
and high hepcidin levels were shown to independently predict inferior survival in this disease 
[12]. In contrast, PV and ET patients were reported to have similar hepcidin levels as healthy 
controls [13]. Hepcidin can be upregulated by excess iron, lower erythropoietic activity and 
variety of inflammatory and microbial stimuli [14]. It binds to iron exporting channel 
ferroportin, which leads to its internalization and degradation, and thereby prevents iron from 
being released from enterocytes and macrophages. This in turn blocks dietary iron absorption 
and release of iron from its stores, as well as reduces bioavailability of iron through lowering 
transferrin saturation (TSAT) [15]. In the context of chronic inflammation / malignant disease 
in general, TSAT of 20% or less is considered to represent functional iron deficiency, despite 
normal or elevated ferritin values [16]. This phenomenon of iron deprivation results in iron-
restricted erythropoiesis and usually manifests with development or worsening of pre-existing 
anemia. Low TSAT, microcytosis and anemia are relatively frequent findings among 
myelofibrosis patients [17, 18]. Clinical and prognostic significance of low TSAT have not 
been investigated in this population so far.  
 
2. Theory  
We hypothesized that low TSAT could potentiate development of anemia in myelofibrosis. 
Therefore, we aimed to investigate TSAT in a population of PMF and SMF patients, to assess 
its clinical associations and potential prognostic value. 
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3. Patients and Methods: 
3.1. Patients 
We retrospectively analyzed a total of 87 patients with myelofibrosis, 64 patients with PMF 
and 23 patients with SMF (15 post-PV, 9 post-ET), that were treated and followed in our 
institution in period from 2004 to 2017. All patients fulfilled the World Health Organization 
(WHO) 2016 criteria for the diagnosis of PMF [1] and the International Working Group for 
Myelofibrosis Research and Treatment (IWG-MRT) criteria for the diagnosis of SMF [7]. A 
total of 72/87 (82.8%) patients were evaluated at the time of diagnosis and 15/87 (17.2%) 
were evaluated at the time of referral to our institution. None of the patients received iron 
supplementation regardless of iron metabolism parameters. All patients provided a written 
informed consent for the molecular analyses. The study was approved by the Institutional 
Review Board. 
 
3.2. Methods 
Patients were staged according to the DIPSS [10]. Bone marrow fibrosis was graded 
according to the current European consensus [19]. Liver and spleen size were assessed by 
palpation. TSAT, ferritin and mean corpuscular volume (MCV) were assessed in addition to 
other demographic, hematological and clinical parameters (age, gender, WBC count, 
differential blood count, circulatory blasts, hemoglobin level, red cell distribution width 
(RDW), platelet count, C reactive protein (CRP) level, lactate dehydrogenase (LDH) level, 
presence of constitutional symptoms, blast phase disease, transfusion dependency, JAK2, 
CALR and MPL mutational status).  
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3.3. Molecular analyses 
For molecular analyses, DNA was isolated from full blood by QIAamp DNA Blood Mini Kit 
(Qiagen, ID 51104). JAK2 V617F was assessed by allele-specific PCR as described 
previously [20], CALR1 and MPL exon 10 mutations were screened by high–resolution 
melting dye assays [21, 22] and any sample sequence that deviated from normal was Sanger 
sequenced. 
 
3.4. Statistical analyses 
The normality of data distribution was tested using the Shapiro-Wilk test. Numerical 
variables were presented as median and interquartile range (IQR), or as arithmetic mean ± 
standard deviation depending on the normality of distribution. Categorical variables were 
presented as proportions. The Mann Whitney U test/the T-test, the χ2 (Chi squared) test and 
the Spearman rank correlation were used where appropriate. Survival analyses were 
performed using the methods of Kaplan and Meier, the Cox-Mantel version of the log-rank 
test [23] and the Cox regression analysis. ROC curve analysis with survival status as a 
classification variable was used for finding an optimal cut-off value for numerical variables 
for the purpose of survival analyses. P values <0.05 were considered statistically significant. 
Associations of different prognostic factors with survival were screened for using a custom 
made MS Excel workbook [24]. Analyses were performed using MedCalc Statistical 
Software version 17.6 (MedCalc Software BVBA, Ostend, Belgium). 
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4. Results: 
4.1. Transferrin saturation in myelofibrosis patients 
There were total of 87 patients with myelofibrosis, 64 with PMF and 23 with SMF. Median 
age was 67 years, IQR (59 - 73), a majority [54/87 (62.1%)] of patients were males. Patients’ 
characteristics are shown in Table 1.  
Median TSAT was 24.5%, IQR (13.8% - 33.8%) and it did not significantly differ between 
PMF and SMF patients [median 25.3% vs 23.5%; P=0.672 (Figure 1A)]. A total of 28/87 
(32.2%) of all patients and 24/72 (33.3%) of newly diagnosed patients presented with TSAT 
20% or lower which did not differ between PMF and SMF patients as well (P=0.834), 
thereby showing that functional iron deficiency is present in a substantial proportion (one 
third) of myelofibrosis patients. 
 
4.2. Clinical associations 
In a cohort of all 87 myelofibrosis patients, lower TSAT as a continuous variable was 
statistically significantly associated with JAK2 mutation [median TSAT 22.2% vs 32.0% for 
JAK2 mutated and wild type patients; P=0.007 (Figure 1C)], transfusion independency 
[median TSAT 23.2% vs 32.7% for transfusion independent and dependent patients; P=0.003 
(Figure 1D)], higher platelets (Rho -0.31; P=0.004), lower MCV (Rho 0.4; P<0.001), lower 
ferritin (Rho 0.72; P<0.001) and higher absolute neutrophil count (Rho -0.25; P=0.027). 
Patients with low TSAT as a categorical variable additionally had significantly lower albumin 
(median albumin 42 g/L vs 45 g/L; P=0.018) and lower absolute lymphocyte count (median 
ALC 1.15 x10
9
/L vs 1.5 x10
9
/L; P=0.041). There was no statistically significant association 
of TSAT with hemoglobin level (Rho -0.19; P=0.083), degree of bone marrow fibrosis (Rho 
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0.03; P=0.818), DIPSS risk category [Rho 0.16; P=0.144 (Figure 1B)] or other measured 
variables. 
In a sub-cohort of 64 PMF patients, lower TSAT remained similarly significantly associated 
with JAK2 mutation (median TSAT 23.0% vs 32.5% for JAK2 mutated and wild type 
patients; P=0.015), transfusion independency (median TSAT 23.0% vs 33.0% for transfusion 
independent and dependent patients P=0.003), higher platelets (Rho -0.34; P=0.006), lower 
MCV (Rho 0.36; P=0.004), lower ferritin (Rho 0.76; P<0.001), lower albumin (median 
albumin 41 g/L vs 45 g/L; P=0.015) and lower absolute lymphocyte count (Rho 0.29; 
P=0.025). There was no clear association with hemoglobin level (Rho -0.18; P=0.149), 
degree of bone marrow fibrosis (Rho -0.02; P=0.869), DIPSS risk category (Rho 0.1; 
P=0.449) or other tested variables. 
 
4.3. Parameters related to iron metabolism and survival 
Although PMF and SMF patients did not differ in overall survival (P=0.362) and TSAT 
(P=0.672), patients with PMF presenting with low TSAT (20% or lower) experienced 
statistically significantly shorter overall survival than PMF patients with TSAT >20% 
[HR=2.43; P=0.017 (Figure 2A)], whereas low TSAT showed no statistically significant 
association with OS in SMF patients [HR=1.48; P=0.623 (Figure 2B)]. PMF patients with 
TSAT ≤10% and TSAT between 10 and 20% experienced similar survival (P=0.822), that 
was worse than in well-saturated patients as said previously. Microcytosis defined as MCV 
<82 fL showed no association with survival in neither of diseases [HR=1.06; P=0.904 for 
PMF (Figure 2C) and HR=2.65; P=0.333 for SMF (Figure 2D)], whereas both PMF and SMF 
patients with ferritin values >686 µg/L [HR=4.49; P=0.003 for PMF (Figure 2E) and 
HR=6.58; P=0.005 for SMF (Figure 2F)] had significantly inferior overall survival when 
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compared to non-iron overloaded patients (optimal cut-off value defined using ROC curve 
analysis). Thus, iron overload bears negative prognostic implications in both diseases, but 
iron deprivation does not seem to have same detrimental effect on survival in SMF as in 
PMF. This implies that substantial differences in iron homeostasis between these two 
diseases could exist. 
We further tested association of low TSAT with inferior overall survival in PMF patients in a 
series of age and gender adjusted multivariate Cox regression models. Due to the implications 
of iron homeostasis on quality of erythropoiesis, we investigated whether effects of low 
TSAT on survival could be mediated through consequences of anemia that is a known 
negative prognostic factor in PMF. Low TSAT and low hemoglobin both retained prognostic 
significance and predicted inferior survival independently of each other in the Cox regression 
model containing low TSAT (HR=4.86; P=0.001), hemoglobin <100 g/L, (HR=11.99; 
P<0.001), age (HR 0.99; P=0.918) and male gender (HR=1.89; P=0.224). This observation is 
in line with lack of significant association of these two parameters that we observed in our 
cohort of PMF patients.  
We also investigated prognostic properties of low TSAT in comparison to transfusion 
dependency with which it was significantly associated, and which is a known negative 
parameter in PMF patients. Both low TSAT and transfusion dependency predicted inferior 
survival independently of each other in the Cox regression model containing low TSAT 
(HR=2.87; P=0.024), transfusion dependency (HR=3.09; P=0.039), age (HR=1.03; P=0.303) 
and male gender (HR=2.03; P=0.190). This is not surprising since low TSAT patients were 
more likely to be transfusion independent.  
We further compared prognostic properties of low TSAT with ferritin values <100 µg/L and 
observed they were independently associated with inferior survival, but in opposite directions 
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in the Cox regression model containing low TSAT (HR=3.62; P=0.020), ferritin <100 µg/L 
(HR=0.21; P=0.019), age (HR=1.0; P=0.932) and male gender (HR=1.25; P=0.702). 
Therefore, low ferritin levels do not seem to bear same prognostic information as low TSAT, 
and ferritin might be better at representing negative effects of iron overload that is probably 
affecting its prognostic properties even at lower cut-off levels. In line with this assumption 
are the optimal cut-off values that were obtained by ROC curve analysis in our patient cohort 
for these two parameters: TSAT at ≤20% and ferritin at >686 µg/L were able to best 
discriminate patients with inferior overall survival in univariate analyses. We further tested 
how do prognostic properties of TSAT and ferritin compare in a subset of transfusion 
independent patients and found that low TSAT (HR=4.15, P=0.047) remained significantly 
associated with inferior survival, while effect of ferritin <100 µg/L was nearly statistically 
significant (HR=0.22, P=0.061) suggesting that described relationships hold even without 
influx of external iron through RBC transfusions.  
We analyzed whether there is an overlap in prognostic properties of different iron metabolism 
related parameters. In the Cox regression model including low TSAT (HR=3.48; P=0.038), 
ferritin >686 µg/L (HR=9.29; P=0.005) and transfusion dependency (HR=1.39; P=0.578), 
only low TSAT and high ferritin remained statistically significantly associated with shorter 
survival. After additionally including anemia in the model, now comparing low TSAT 
(HR=8.16; P=0.003), hemoglobin <100 g/L (HR 21.47; P=0.002), ferritin >686 µg/L 
(HR=9.32; P=0.008) and transfusion dependency (HR=0.52; P=0.287), we observed that low 
TSAT remained significantly associated with shorter survival and predicted worse prognosis 
independently of anemia and high ferritin levels. Univariate effect of transfusion dependency 
was probably mediated through iron overload and was lost after controlling for other 
parameters. Same associations with survival were retained after additionally adjusting model 
for age and gender, Table 2.  
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In addition, we compared negative prognostic significance of low TSAT to DIPSS prognostic 
scoring system. Low TSAT predicted shorter survival when compared to each of the 
components of DIPSS score individually, as well as when analyzed in the Cox regression 
model containing low TSAT (HR=14.07; P<0.001), age >65 years (HR=0.71; P=0.399), 
constitutional symptoms (HR=4.33; P=0.037), WBC >25 x109/L (HR=13.51; P<0.001), >1% 
circulatory blasts (HR=0.01; P=0.917), hemoglobin <100 g/L (HR=20.07; P<0.001) and male 
gender (HR=1.54; P=0.214). Low TSAT (HR=4.36; P=0.002) remained statistically 
significant when compared to DIPSS itself (HR=4.74; P<0.001), as well.  
 
5. Discussion: 
To the best of our knowledge, our study is first to report that low TSAT has detrimental effect 
on survival of PMF patients. This effect is independent of anemia, and of ferritin levels that 
seem to be better at representing iron overload in PMF patients. 
Our data show that one third of myelofibrosis patients experience low TSAT. These patients 
are more likely to be transfusion independent, JAK2 mutated and to have higher platelets, 
hence usually not considered to be under elevated risk of death. There was similar 
distribution of TSAT values over different DIPSS risk categories and low TSAT predicted 
inferior survival independently of DIPSS, further implying that patients with low TSAT 
remain unrecognized through standard process or risk stratification.  
TSAT and ferritin levels were strongly correlated and patients with low TSAT had reduced 
iron stores (median ferritin 49.5 µg/L vs 309 µg/L). Ferritin is of limited value in estimating 
iron deficiency status in PMF as it forms a part of inflammatory response and can be 
artificially elevated. As our data suggest, lower ferritin is protective in PMF, even at low cut-
off points and might be more sensitive to detect adverse effects of iron overload, than iron 
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deficiency. This effect of ferritin on survival is overlapping with transfusion dependency, but 
it is possible, although not clear at the moment, that adverse effect of higher ferritin holds 
even in transfusion independent patients. Our study was underpowered to properly investigate 
this issue. Evaluation of bone marrow iron stores is also of limited usefulness as it was shown 
that up to 75% of PMF patients have diminished or absent iron deposits but this finding was 
not associated with decreased ferritin levels [25]. This phenomenon could be due to 
extramedullary hematopoiesis in the spleen that dominates iron uptake, and thus restrains iron 
supply to the bone marrow [26]. Due to aforementioned problems, some authors proposed 
low TSAT as a parameter of choice to evaluate iron deficiency in PMF [17]. Low TSAT 
could be a consequence of absolute or functional iron deficiency, but this is challenging to 
discriminate. Either way, low TSAT patients surely suffer from reduced iron bioavailability. 
Functional iron deficiency in anemia of chronic disease develops due to elevated hepcidin 
that impairs iron utilization from its stores [16]. Abnormally high levels of hepcidin were 
reported in a population of PMF patients [12] and are probably contributing to low TSAT. 
Aforementioned study did not assess correlation between hepcidin and TSAT, but reported 
correlation between high hepcidin and high ferritin levels which could predict inferior 
survival independently of each other. In contrast to PMF, hepcidin levels in PV and ET were 
reported to be similar to healthy controls [13] illustrating that significant differences in iron 
homeostasis between different Ph- MPNs exist. Our study suggests that patients with SMF, 
although experiencing similar levels of TSAT, do not have same adverse effect of low TSAT 
on survival as PMF patients. Our SMF cohort consisted mostly of post-PV SMF patients. 
Therapeutic phlebotomies are the mainstay of PV treatment and they result in hematocrit 
reduction and depletion of iron stores [27]. Phlebotomies improve survival in PV, but it is not 
clear how do they reflect on the biology of leukemic stem cell. It could be however, that 
positive iron deprivation associated effects are retained even after disease transformation into 
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myelofibrosis. One should be aware that regulation of iron stores, especially in the context of 
inflammation, is incompletely understood process and discordant results regarding prognostic 
value of reduced/increased iron availability are present in the literature. Increased TSAT was 
reported to predict higher mortality in critically ill patients [28] and to be associated with 
higher risk of cancer death [29]. On the opposite, low TSAT was reported to be associated 
with increased cardiovascular and all cause mortality [30], as well as with more advanced 
disease features and poor performance status in cancer patients [31]. To add to the confusion, 
one study reported that both low and high TSAT were associated with increased total and 
cardiovascular mortality, hazards for low TSAT being more pronounced [32]. These 
conflicting data probably reflect changes in iron regulation specific to different clinical 
settings and different studied populations, and emphasize the fact that there are two edges of 
the “iron sword”.  
We hypothesized that low TSAT could potentiate development of anemia in myelofibrosis. 
Interestingly, low TSAT was observed regardless of anemia severity and was not correlated 
with hemoglobin level as expected. It should be noted that factors like transfusion 
dependency and JAK2 mutation might disguise relationship between TSAT and hemoglobin. 
RBC transfusions are given in severe anemia and result in an increase of TSAT due to the 
introduction of excess iron. JAK2 mutated patients have stronger proliferative potential of 
disease with significantly higher hemoglobin and absolute neutrophil count (data not shown), 
but also lower TSAT. This might be due to increased iron utilization associated with 
increased erythropoiesis or due to changes in inflammatory profile associated with JAK2 
mutation. Nevertheless, TSAT affected quality of erythropoiesis, as observed by decrease in 
MCV associated with lower TSAT values. Two author groups previously investigated 
properties of microcytosis in a population of PMF patients [17, 18]. They found that although 
microcytosis was relatively frequent (28% and 24% of untreated patients), it had no 
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association with overall survival. It was also reported that microcytosis showed significant 
association with low TSAT, both univariately and after adjustment for other correlated 
factors, but had no association with anemia [17]. Our results are in line with these findings. 
Oppositely to microcytosis, higher heterogeneity of erythrocyte size (i.e. anisocytosis, 
measured as RDW) seems to be associated with anemia and predictive of inferior survival, 
but not correlated with iron metabolism parameters in PMF [33]. These findings indicate that 
MCV and RDW, although useful for recognition of iron deficiency anemia in general 
population, might be suboptimal for this purpose in PMF. Patients with low TSAT were also 
more likely to have lower absolute lymphocyte count and lower albumin concentration. 
These could indicate worse nutritional status or higher inflammatory atmosphere and were 
shown to be predictive of inferior survival in myelofibrosis independently of each other and 
DIPSS [34]. Thus, numerous pathophysiologic processes modulate TSAT and are reflected in 
its reduction. 
Considering information presented above, challenging questions about possible therapeutic 
options emerge. First, would PMF patients with low TSAT benefit from iron 
supplementation? Due to dangers associated with iron overload [35] (which are evident from 
our data as well), it is hard to identify who would be candidates for such therapy, but these 
would probably need to be transfusion independent patients. Intravenous iron might 
overcome hepcidin mediated iron restriction and improves erythropoiesis in a context of 
anemia in different malignancies [16]. TSAT had no association with hemoglobin level (it 
was predictive of inferior survival on different levels of anemia), but was associated with 
microcytosis indicating that link with quality of erythropoiesis in PMF exists. Therefore, low 
TSAT, but non transfusion dependent patients with stable disease seem to be the population 
of interest. Second, would PMF patients with low TSAT benefit from therapies that increase 
iron utilization? Compounds that inhibit expression or effects of hepcidin seem to be 
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promising in the context of anemia associated with chronic disease [36]. As mentioned 
previously, same concerns with possible development of iron overload in context of 
myelofibrosis and such drugs would exist. Ruxolitinib, JAK inhibitor that already found its 
place in treatment of myelofibrosis, was reported to improve iron metabolism indices in a 
population of PV patients [37]. This analysis was exploratory, only descriptive statistics were 
used and it is yet unclear if these improvements are associated with clinical benefit in PV. It 
would be interesting to see if similar associations are present in patients with myelofibrosis 
and how do potential changes in iron indices translate into clinical outcomes. 
Main limitations of our study are retrospective study design, small number of patients, single 
center experience and unavailable data on hepcidin. We were unable to assess various 
mechanisms that potentially modulate TSAT on different biological levels (especially the role 
of pro-inflammatory environment in the bone marrow and the spleen). We also acknowledge 
that our study could be underpowered to detect statistical significance of some associations 
that we did investigate. Nevertheless, our findings implicate there is a substantial subset of 
PMF patients that might experience shorter survival associated with low TSAT. It would be 
of interest to further investigate relationship between hepcidin expression, ferritin and TSAT 
and potential overlap of their prognostic properties in populations of transfusion dependent 
and independent myelofibrosis patients. 
 
6. Conclusion 
One third of myelofibrosis patients experience low TSAT. Both iron deprivation (low TSAT), 
anemia and iron overload (high ferritin) seem to be independently hazardous for PMF 
patients, whereas low TSAT seems not to affect survival in SMF. It remains a challenging 
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question whether there is a subset of PMF patients that would benefit from iron 
supplementation therapy. 
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Table 1: Patients’ characteristics (all myelofibrosis patients). * statistically significant at 
P<0.05. ** statistically significant at P<0.05 when TSAT is used as a continuous variable. 
 All patients 
Transferrin sat. 
≤20% 
Transferrin sat. 
>20% 
P value 
Number of 
patients 
87 28 (32.2%) 59 (67.8%) - 
Age (years) 
67 IQR (59 - 
73) 
66.5 IQR (62.8 - 
73.3) 
67 IQR (57.5 - 
73) 
0.418 
Male gender 54/87 (62.1%) 14/28 (50%) 40/59 (67.8%) 0.110 
Transferrin 
saturation (%) 
24.5 IQR (13.8 
- 33-8) 
7.6% IQR 
(5.5% - 12.8%) 
32 IQR (24.4 – 
37.3) 
<0.001 * 
Hemoglobin 
level (g/L) 
109 IQR (94.3 - 
137.3) 
108.5 IQR (96 - 
146.8) 
109 IQR (88.3 - 
131.5) 
0.191 
MCV (fL) 
87.3 IQR (80.8 
- 93.3) 
81.7 IQR (76.4 - 
87.8) 
89.5 IQR (84.8 - 
94.8) 
0.003 * 
Microcytosis 
(MCV <82 fL) 
23/84 (27.4%) 15/28 (53.6%) 8/56 (14.3%) <0.001 * 
RDW (%) 
19.4 IQR (17.5 
- 20.7) 
19.6 IQR (18.6 - 
21.4) 
19.3 IQR (17 - 
20.3) 
0.099 
WBC (x10
9
/L) 
10.9 IQR (6.8 - 
16.3) 
13.6 IQR (8 - 
19.3) 
9.8 IQR (6.4 - 
15.6) 
0.120 
>1% circulatory 
blasts 
31/87 (35.6%) 9/28 (32.1%) 22/59 (37.3%) 0.640 
Platelets 351 IQR (174.8 411 IQR (258.3 333 IQR (166 - 0.192 ** 
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(x10
9
/L) - 575.5) - 688.5) 559.5) 
Ferritin (µg/L) 
187 IQR (63 - 
421) 
49.5 IQR (16.2 - 
143) 
309 IQR (186 - 
628.5) 
<0.001 * 
LDH (U/L) 
539.5 IQR 
(351.5 - 780) 
636 IQR (393 - 
859) 
513 IQR (348 - 
758) 
0.363 
CRP (mg/L) 
4.7 IQR (1.3 - 
13.6) 
4.9 IQR (2 - 16) 
4 IQR (1.3 - 
11.1) 
0.534 
Albumin (g/L) 
44 IQR (40 - 
46) 
42 IQR (40 - 44) 45 IQR (42 - 47) 0.018 * 
Advanced bone 
marrow fibrosis 
50/87 (57.5%) 16/28 (57.1%) 34/59 (57.6%) 0.966 
JAK2 mutated 50/83 (60.2%) 21/27 (77.8%) 29/56 (51.8%) 0.023 * 
CALR mutated 8/60 (13.3%) 1/22 (4.5%) 7/38 (18.4%) 0.238 
MPL mutated 1/60 (1.7%) 1/22 (4.5%) 0/38 (0%) 0.367 
Constitutional 
symptoms 
30/86 (34.9%) 9/28 (32.1%) 21/58 (36.2%) 0.711 
Massive 
splenomegaly 
26/82 (31.7%) 11/27 (40.7%) 15/55 (27.3%) 0.218 
Blast phase 
disease 
8/87 (9.2%) 2/28 (7.1%) 6/59 (10.2%) 1.000 
Transfusion 
dependency 
22/87 (25.3%) 3/28 (10.7%) 19/59 (32.2%) 0.031 * 
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Table 2: Cox regression model investigating prognostic properties of different parameters 
related to iron metabolism, adjusted for age and gender. Abbreviations: TSAT – transferrin 
saturation. * statistically significant at P<0.05. 
Variable Hazard ratio 
95% confidence 
interval 
P value 
TSAT ≤20% HR=15.71 [2.69 - 91.66] 0.002 * 
Hemoglobin <100 g/L HR=37.15 [4.5 - 306.5] 0.001 * 
Ferritin >686 µg/L HR=10.39 [1.44 - 75.02] 0.020 * 
Transfusion dependency HR=0.96 [0.21 - 4.29] 0.956 
Age HR=1.01 [0.92 - 1.11] 0.842 
Male gender HR=4.84 [0.82 - 28.42] 0.081 
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Figure 1: A) Transferrin saturation (TSAT) did not differ between primary (PMF) and 
secondary myelofibrosis (SMF) patients and B) did not differ between the Dynamic 
International Prognostic Scoring System (DIPSS) risk categories (1 – low risk; 2 – 
intermediate-1 risk; 3 – intermediate-2 risk; 4 – high risk). C) Janus-kinase-2 (JAK2) V617F 
mutated patients had significantly lower TSAT. D) Transfusion dependent patients had 
significantly higher TSAT.
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Figure 2: A) Low transferrin saturation (TSAT) was associated with inferior overall survival 
(OS) in primary myelofibrosis (PMF) patients, B) whereas there was no statistically 
significant association with survival in patients with secondary myelofibrosis (SMF). C) 
Mean corpuscular volume (MCV) had no impact on survival of patients with PMF and D) 
SMF. E) High ferritin was associated with inferior survival in both PMF and F) SMF 
patients. 
 
